Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants
Nicole Espy(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Stephen R. Walsh(Beth Israel Deaconess Medical Center), Michael Stirewalt(Infectious Disease Research Institute), Georgia D. Tomaras(National Institutes of Health), Jessica Andriesen(Adaptive Biotechnologies (United States)), Erin A. Goecker, Esther Kwara(Brigham and Women's Hospital), Shannon Grant(Fred Hutch Cancer Center), Xue Han(Fred Hutch Cancer Center), Kelly E. Seaton(International Vaccine Institute), Bharathi Lakshminarayanan(Fred Hutch Cancer Center), Yunda Huang(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 7
Related Papers
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
|The Lancet|2008|708
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
|New England Journal of Medicine|2022|649
Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia
|Journal of Virology|2008|624
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
|New England Journal of Medicine|2013|586
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
|New England Journal of Medicine|2021|557